Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML and Oligoblastic AML

NCT03175978 is registered in ClinicalTrials.gov with IGF Oncology, LLC as lead sponsor.

NCT NCT03175978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03175978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML and Oligoblastic AML
Lead sponsor
IGF Oncology, LLC
Phase
Phase 1/2
Overall status
Terminated
Start date
February 21, 2018
Completion date
September 30, 2021
Enrollment
2 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, refractory, with excess of blasts, leukemia, myelomonocytic, chronic, myelodysplastic syndromes